← Human Trials & Peer-Reviewed Studies
Slow Age: Interventions to Slow Aging in Humans
Plain-language guide to NCT05593939: phase 2 randomized trial of NAD+, 80 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT05593939
- Phase
- phase 2
- Status
- completed
- Start
- 2022-05-01
- Completion (planned or actual)
- 2022-12-21
- Participants
- 80 (actual)
- Design
- randomized, open label (everyone knows who gets what), prevention
- Conditions studied
- Aging
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 2 trial tested NAD+.
It had four arms (groups): Exercise arm (experimental), Time restricted feeding (experimental), Nicotinamide riboside (experimental) and Control (no intervention).
The registry classes the interventions as behavioral and dietary supplement.
Who Took Part
The registry lists 80 actual participants took part.
It was open to people of any sex aged from 65 years with no upper age limit.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study. Aged ≥ 65 years.
The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: inability or unwillingness to take oral supplements; inability or unwillingness to adhere to the fasting regiment; inability or unwillingness to perform the prescribed physical exercise.
How the Study Was Run
The set-up was randomized, parallel-group and open-label.
The participants were allocated by chance, so the NAD+ group and the comparison group should start out alike.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Nothing was hidden in this open-label NAD+ study: the participants and staff both knew the treatment.
It started in 2022-05-01 with completion listed for 2022-12-21.
It ran at 1 site in Denmark.
Its stated primary purpose is prevention.
What Was Measured
Researchers chose this as the main measure: Interleukin-6 levels in plasma (time frame: Day 1 compared to day 84).
It also tracked 12 secondary outcomes, for example Concentration of CRP in plasma, Concentration of TNF-α in plasma, Concentration of NAD in whole blood, Change in fat mass, Change in lean mass and Grip strength.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of NAD+ in 80 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the NAD+ compound page, all human trials.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.